Leukemia

A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

JZP458 is part of a multi-agent chemotherapy regimen for lymphoblastic lymphoma and acute lymphoblastic leukemia, and can be used for adult and pediatric patients.

Data from a phase 1b dose escalation and expansion study highlight an encouraging duration of remission using APVO436 plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Data from the phase 3 QuANTUM-First trial support the FDA’s approval of quizartinib for managing FLT3-ITD–positive acute myeloid leukemia.

Findings from a phase 2 study may inform the design of future trials assessing fecal microbiota transplants in patients with acute myeloid leukemia.

Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.

The agent will be evaluated in a phase 1 study for patients with several myeloid malignancies, in which investigators will identify a recommended phase 2 dose.

Pediatric patients with acute lymphoblastic leukemia and have KMT2A rearrangements were evaluated in a recent study published in the British Journal of Haematology.

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

The combination of venetoclax and ibrutinib may yield long-lasting treatment-free remission among patients with high-risk chronic lymphocytic leukemia.

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia and minimal residual disease of 0.01% or more.

Investigators pause their evaluation of SC-DARIC33 in pediatric relapsed/refractory acute myeloid leukemia following a grade 5 serious adverse effect in the phase 1 PLAT-08 trial.

Thought leaders from various institutions offered their take on the most practice-changing trial that came out of the 2023 ASCO Annual Meeting.

Thought leaders from various institutions offered their take on the biggest surprise that came out of the 2023 ASCO Annual Meeting.

Investigators identify only 1 death related to treatment with acalabrutinib among older, frail patients with chronic lymphocytic leukemia in the phase 2 CLL-FRAIL trial.

Adding blinatumomab to Interfant-06 chemotherapy appears to be feasible and safe in the treatment infants with acute lymphoblastic leukemia in a phase 2 trial.

Zanubrutinib and acalabrutinib produce similar safety profiles in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND and APLINE trials.

Venetoclax plus obinutuzumab with or without ibrutinib demonstrates superiority over standard chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.

Treatment with lisocabtagene maraleucel correlates with a reduction in CD19-positive cells in responders and patients with stable disease among those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 1/2 TRANSCEND CLL 004 trial.

A real-world population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia are reported to have had a high rate of complete remissions following treatment with brexucabtagene autoleucel.

Obecatagene autoleucel also appears to result in a high rate of minimal residual disease negativity in a population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Zanubrutinib appears to produce significantly better progression-free survival and overall cardiac safety compared with ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Sustained improvements in leukemia outcomes in low- and middle-income countries are feasible with cross border programs, according to an expert from the University of California, San Diego.

Voruciclib plus venetoclax appears to yield no dose-limiting toxicities in a small population of patients with acute myeloid leukemia, according to early findings from a phase 1 study.